Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. is actively engaging with investors through a virtual presentation, highlighting its biopharmaceutical pipeline and recent developments in its product candidates [1][2]. Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on pain management therapies and vaccines for public health challenges [4]. - The company is advancing TNX-102 SL, a candidate for fibromyalgia management, with a New Drug Application (NDA) submitted based on two significant Phase 3 studies, and a PDUFA goal date set for August 15, 2025 [4]. - TNX-102 SL has received Fast Track designation from the FDA for fibromyalgia management and is also being studied for acute stress reactions and disorders [4]. - The CNS portfolio includes TNX-1300, a biologic in Phase 2 for cocaine intoxication, which has FDA Breakthrough Therapy designation [4]. - Tonix's immunology portfolio features TNX-1500, a monoclonal antibody for organ transplant rejection and autoimmune diseases, which has completed a positive Phase I trial [4]. - The infectious disease portfolio includes TNX-801, a vaccine for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent with a contract worth up to $34 million with the U.S. Department of Defense [4]. Upcoming Events - Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, will present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025, at 3:30 p.m. ET [1]. - Investors can pre-register for the event and will have the opportunity to ask questions in real-time [2][3].